Contineum Therapeutics, Inc. CTNM

CTNM Company Overview

Contineum Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of small‑molecule therapeutics for serious diseases with significant unmet medical need. Based on publicly available regulatory filings and market disclosures, the company primarily operates within the biotechnology and pharmaceutical research industries, with an emphasis on central nervous system (CNS) and immune‑mediated or inflammatory disorders. The company does not currently market any approved products and does not generate commercial product revenue.

The company was formed to advance a precision‑medicine approach using targeted small molecules designed to modulate specific biological pathways. Its strategy centers on developing orally administered therapies intended to offer differentiated efficacy, safety, or convenience compared with existing treatment options. Data inconclusive based on available public sources regarding the exact year of founding and detailed early corporate evolution, though the company became publicly listed in the United States in 2024 following an initial public offering.